Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Docetaxel in R/M HNSCC
NCT02718820Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2016
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Medical University of Vienna. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02718820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718820.